(Total Views: 512)
Posted On: 12/28/2020 2:56:01 PM
Post# of 153915
Re: ClosetInvestor #69958
Closet wrote,
CYDY has definitely enrolled slowly, too slowly. But if Leron is a sudden overwhelming success with Covid, its name (or okay, Vyrologix's name) will become a household world, and the power of celebrity in America -- where fame is everything -- will make enrollment painlessly swift.
And soon CYDY could well have plenty of pennies to pump into trials like NASH. Personally, that's exactly what I hope the company spends its first billions on: trying to ascertain which indications are the sitting ducks....and ... WHAM! Give this company a big pink teddybear, ladies and gentlemen, we have a winner!
Quote:
Honestly, the NASH trial is a non-factor until later 2021 or early 2022, unless enrollment is fast. CYDY and other biotechs typically enroll trials slowly due to cost and reach.
CYDY has definitely enrolled slowly, too slowly. But if Leron is a sudden overwhelming success with Covid, its name (or okay, Vyrologix's name) will become a household world, and the power of celebrity in America -- where fame is everything -- will make enrollment painlessly swift.
And soon CYDY could well have plenty of pennies to pump into trials like NASH. Personally, that's exactly what I hope the company spends its first billions on: trying to ascertain which indications are the sitting ducks....and ... WHAM! Give this company a big pink teddybear, ladies and gentlemen, we have a winner!
(3)
(0)
